Correction

Correction: The potent and selective cyclin-dependent kinases 4 and 6 inhibitor ribociclib (LEE011) is a versatile combination partner in preclinical cancer models

Sunkyu Kim[1], Ralph Tiedt[2], Alice Loo[1], Thomas Horn[1], Scott Delach[1], Steven Kovats[1], Kristy Haas[1], Barbara Schacher Engstler[2], Alexander Cao[1], Maria Pinzon-Ortiz[1], Iain Mulford[1], Michael G. Acker[1], Rajiv Chopra[3], Christopher Brain[4], Emmanuelle di Tomaso[1], William R. Sellers[1] and Giordano Caponigro[1]

[1]Novartis Institutes for BioMedical Research, Oncology Disease Area, Cambridge, MA, USA
[2]Novartis Institutes for BioMedical Research, Oncology Disease Area, Basel, Switzerland, USA
[3]Novartis Institutes for BioMedical Research, Chemical Biology & Therapeutics, Cambridge, MA, USA
[4]Novartis Institutes for BioMedical Research, Global Discovery Chemistry, Cambridge, MA, USA

Published: *April 07, 2020*

This article has been corrected: In Table 1, a unit of measurement is displayed incorrectly. "μM" is used instead of "nM". The corrected Table 1 is shown below. The authors declare that these corrections do not change the results or conclusions of this paper.

Original article: Oncotarget. 2018; 9:35226–35240. https://doi.org/10.18632/oncotarget.26215

Table 1: IC_{50} Values of CDK4/6 Inhibitors

Cell line	Cancer type	Dominant CDK	Ribociclib IC_{50}, mean ± SD, nM	Palbociclib IC_{50}, mean ± SD, nM	Abemaciclib IC_{50}, mean ± SD, nM
JeKo-1	MCL	CDK4	143 ± 87	72 ± 33	20 ± 9
CAMA-1	ER+ BC	CDK4	162 ± 59	50 ± 24	28 ± 2
MCF-7	ER+ BC	CDK4	62 ± 30	30 ± 18	11 ± 7
T47D	ER+ BC	CDK4	111 ± 14	66 ± 19	13 ± 3
REH	ALL	CDK6	1030 ± 246	60 ± 17	72 ± 6
SEM	ALL	CDK6	1484±215	87 ± 28	162 ± 37
Pfeiffer	DLBCL	CDK6	948 ± 53	89 ± 32	66 ± 25
MOLM-13	AML	CDK6	365 ± 62	47 ± 25	57 ± 21

IC_{50}values (mean ± SD) of ribociclib, palbociclib, and abemaciclib were determined using the CyQuant cell proliferation assay. The average differential for CDK4 versus CDK6 dependent lines for ribociclib, palbociclib, and abemaciclib is 8.0-, 1.3-, and 5.5-fold, respectively. Abbreviations: ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; BC, breast cancer; CDK, cyclin-dependent kinase; DLBCL, diffuse large B-cell lymphoma; ER+, estrogen receptor-positive; IC_{50}, half-maximal inhibitory concentration; MCL, mantle-cell lymphoma; SD, standard deviation.